Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV – Get Free Report) was the recipient of a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 182 shares, a drop of 55.6% from the December 31st total of 410 shares. Based on an average daily volume of 905 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are sold short. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 905 shares, the short-interest ratio is presently 0.2 days.
Mosaic ImmunoEngineering Stock Performance
CPMV traded down $0.03 on Friday, hitting $0.58. 500 shares of the company were exchanged, compared to its average volume of 623. The business’s fifty day moving average is $0.50 and its 200 day moving average is $0.56. Mosaic ImmunoEngineering has a fifty-two week low of $0.25 and a fifty-two week high of $1.05. The firm has a market capitalization of $4.16 million, a P/E ratio of -6.39 and a beta of -0.82.
Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) last posted its quarterly earnings data on Wednesday, November 19th. The company reported ($0.02) earnings per share for the quarter.
Mosaic ImmunoEngineering Company Profile
Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.
Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.
Read More
- Five stocks we like better than Mosaic ImmunoEngineering
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
